stockrow
Friday 6 November 2026
Export MXCT’s income statement to Excel — free account
MaxCyte, Inc.
MXCT Healthcare Medical Devices
MaxCyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $33.0 million, down 14.5% from fiscal 2024.
- Revenue
- −14.5%
- EPS
- +33.3%
- Free cash flow
- +54.7%
Quarter to June 2026, against a year earlier
1.30
0.01
−0.76%
Follow MXCT
Alert me
MaxCyte, Inc. (MXCT) P/E ratio
MaxCyte, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 22 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| APYX Apyx Medical Corporation compare | n/m |
| OWLT Owlet, Inc. compare | n/m |
| RXST RxSight, Inc. compare | n/m |
| INGN Inogen, Inc compare | n/m |
| STIM Neuronetics, Inc. compare | n/m |
| MXCT MaxCyte, Inc. | n/m |
| CATX Perspective Therapeutics, Inc. compare | n/m |
| LUNG Pulmonx Corporation compare | n/m |
| QTRX Quanterix Corporation compare | n/m |
| Medical Devices industry median | 25.6× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)